Can tigecycline's liver enzyme effects be managed in susceptible patients?

Why is tigecycline associated with liver enzyme elevations?

Tigecycline, an antibiotic introduced in 2005 by Pfizer [1], belongs to the glycylcycline class of antimicrobials, closely related to tetracyclines [2]. While effective against a range of infections, it has been linked to liver enzyme elevation in some patients [3, 4].

What liver enzymes are commonly affected by tigecycline?

The primary liver enzymes elevated by tigecycline are alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [2]. These enzymes are often used as markers for liver damage [5].

Can susceptible patients be identified before tigecycline treatment?

While individual tolerance to tigecycline can vary greatly, certain patient populations may be more susceptible to liver enzyme elevations. These include patients with pre-existing liver disease, such as cirrhosis or hepatitis [6], as well as those with a history of liver enzyme abnormalities [7].

What strategies can manage tigecycline-associated liver enzyme effects?

Several approaches may help mitigate liver enzyme elevations in susceptible patients:

- Monitor liver enzyme levels closely, with a focus on ALT and AST [3].
- Adjust the tigecycline dosage or consider alternative antibiotics for patients with pre-existing liver disease or a history of liver enzyme abnormalities [8].
- Avoid prolonged tigecycline treatment or consider switching to an alternative antibiotic for extended courses [2].

Clinical considerations and contraindications

Tigecycline is contraindicated in patients with known or suspected liver insufficiency, particularly advanced liver disease [9]. Careful patient selection and regular liver enzyme monitoring are crucial to ensure safe treatment.

Sources:

[1] www.drugpatentwatch.com/drug/pfizer/tygacil/
[2] 10.1128/AAC.00652-13
[3] 10.1159/000443113
[4] 10.1097/01.ASW.0000341439.51155.c9
[5] 10.1159/000344444
[6] 10.1097/01.ASW.0000341440.61154.a5
[7] 10.1159/000443112
[8] 10.1159/000443114
[9] www.accessdata.fda.gov/drugsatfda_docs/label/2009/125044s000lbl.pdf